AG2001

Phase 3Small molecule

Ahn-Gook Pharmaceuticals Co.,Ltd

AG2001 is one of 6 small molecule programs targeting Acute bronchitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute BronchitisNot yet recruiting

Acute BronchitisPhase 3

Not yet recruiting

Competition

Competitive Landscape

5 competitors in Acute Bronchitis

#DrugCompanyPhaseTrials

Ceftin

PPhiladelphia Eye Associates

Approved

—2

AG2001

Ahn-Gook Pharmaceuticals Co.,Ltd

Phase 3

1 3

Primsol

CConrado Roberto Hoffmann Filho

Preclinical

1 4

Mucinex

RReckitt Benckiser LLC

Preclinical

1 5

Gantanol

CConrado Roberto Hoffmann Filho

Preclinical

1 6

Atrovent

Boehringer Ingelheim

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Not yet recruiting

Acute Bronchitis

NCT07198347

Clinical

Trials by Indication[1]

Acute bronchitis1 trial

Efficacy and Safety of AG2001 in Patients With Acute Bronchitis

Not yet recruiting· Ahn-Gook Pharmaceuticals Co.,Ltd logo

Ahn-Gook Pharmaceuticals Co.,Ltd·Phase 3·NCT07198347·300 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for AG2001. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AG2001 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AG2001. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ahn-Gook Pharmaceuticals Co.,Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Ahn-Gook Pharmaceuticals Co.,Ltd

AG2001

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Acute bronchitis1 trial

References

Drug Info

Quick Facts

Related News